Loading stock data…
VRCA
$6.27-0.10 (-1.57%)
Market ClosedLast close May 1
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Verrica Pharmaceuticals Inc. in the Healthcare sector is trading at $6.27. The stock is currently 36% below its 52-week high of $9.82, remaining 6.3% above its 200-day moving average. Technical signals show neutral RSI of 64 and bullish MACD crossover, explaining why VRCA maintains its current momentum and trend strength. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 64) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$6.27
Potential Upside
5%
Whystock Fair Value$6.58
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus4 analysts
Mean target$16.50+163.2%
Range$10.00 – $20.00
Fundamentals
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combin...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$113.34M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.43
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-72.29%
Volume
Today's trading volume
25,276
Recent News
Verrica Pharmaceuticals Inc (VRCA) Q4 2025 Earnings Call Highlights: Record Revenue Growth and ...
Verrica Pharmaceuticals Inc (VRCA) reports a 368% increase in annual revenue and extends its cash runway into 2027, despite challenges in sales force and competition.
Verrica Pharmaceuticals Q4 Earnings Call Highlights
Verrica Pharmaceuticals (NASDAQ:VRCA) used its fourth quarter and year-end 2025 corporate update call to highlight what management described as a “fundamental” business transformation driven by sharper commercial execution, pipeline progress, and a strengthened balance sheet. YCANTH commercial trac
Verrica Pharmaceuticals (VRCA) Upgraded to Strong Buy: Here's Why
Verrica Pharmaceuticals (VRCA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
New Strong Buy Stocks for February 2nd
LUV, VRCA, CVLT, FINW and SDVKY have been added to the Zacks Rank #1 (Strong Buy) List on February 2, 2026.
How Much Upside is Left in Verrica Pharmaceuticals (VRCA)? Wall Street Analysts Think 97.11%
The mean of analysts' price targets for Verrica Pharmaceuticals (VRCA) points to a 97.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.